Am J Psychiatry 155:1247-1253, September 1998
©Copyright 1998 American Psychiatric Association
Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment
Frederick W. Reimherr, M.D.,
Jay D. Amsterdam, M.D.,
Frederic M. Quitkin, M.D.,
Jerrold F. Rosenbaum, M.D.,
Maurizio Fava, M.D.,
John Zajecka, M.D.,
Charles M. Beasley, Jr., M.D.,
David Michelson, M.D.,
Paul Roback, M.S., and
Karen Sundell, B.S.
Objective: The purpose of this study was to determine prospectively the optimal length of therapy in a long-term, placebo-controlled continuation study of patients who responded to acute fluoxetine treatment for major depression (defined by DSM-III-R). Method: The study was conducted at five outpatient psychiatric clinics in the United States. Patients who met criteria for remission after 12 or 14 weeks of open-label acute fluoxetine therapy, 20 mg/day (N=395 of 839 patients), were randomly assigned to one of four arms of a double-blind treatment study (50 weeks of placebo, 14 weeks of fluoxetine and then 36 weeks of placebo, 38 weeks of fluoxetine and then 12 weeks of placebo, or 50 weeks of fluoxetine). Relapse rate was the primary outcome measure. Both Kaplan-Meier estimates and observed relapse rates were assessed in three fixed 12-week intervals after double-blind transfers from fluoxetine to placebo at the start of the double-blind period and after 14 and 38 weeks of continued fluoxetine treatment.Results: Relapse rates (Kaplan-Meier estimates) were lower among the patients who continued to take fluoxetine compared with those transferred to placebo in both the first interval, after 24 total weeks of treatment (fluoxetine, 26.4%; placebo, 48.6%), and the second interval, after 38 total weeks of treatment (fluoxetine, 9.0%; placebo, 23.2%). In the third interval, after 62 total weeks of treatment, rates were not significantly different between the groups (fluoxetine, 10.7%; placebo, 16.2%). Conclusions: Patients treated with fluoxetine for 12 weeks whose depressive symptoms remit should continue treatment with fluoxetine for at least an additional 26 weeks to minimize the risk of relapse. Am J Psychiatry 1998; 155: 1247-1253
This article has been cited by other articles:
|
|
|
|
 
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
J Psychopharmacol,
June 1, 2008;
22(4):
343 - 396.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. J. Emslie, B. D. Kennard, T. L. Mayes, J. Nightingale-Teresi, T. Carmody, C. W. Hughes, A. J. Rush, R. Tao, and J. W. Rintelmann
Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
Am J Psychiatry,
April 1, 2008;
165(4):
459 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. DeRubeis, S. D. Hollon, J. D. Amsterdam, R. C. Shelton, P. R. Young, R. M. Salomon, J. P. O'Reardon, M. L. Lovett, M. M. Gladis, L. L. Brown, et al.
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
Arch Gen Psychiatry,
April 1, 2005;
62(4):
409 - 416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Hollon, R. J. DeRubeis, R. C. Shelton, J. D. Amsterdam, R. M. Salomon, J. P. O'Reardon, M. L. Lovett, P. R. Young, K. L. Haman, B. B. Freeman, et al.
Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression
Arch Gen Psychiatry,
April 1, 2005;
62(4):
417 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Jindal, D. J. Buysse, and M. E. Thase
Maintenance Treatment of Insomnia: What Can We Learn From the Depression Literature?
Am J Psychiatry,
January 1, 2004;
161(1):
19 - 24.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. B. Keller
Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: Remission and Beyond
JAMA,
June 18, 2003;
289(23):
3152 - 3160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. MARTENYI, E. B. BROWN, H. ZHANG, S. C. KOKE, and A. PRAKASH
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
The British Journal of Psychiatry,
October 1, 2002;
181(4):
315 - 320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. A. HIRSCHFELD
Clinical importance of long-term antidepressant treatment
The British Journal of Psychiatry,
September 1, 2001;
179
(42):
s4 - s8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. DONOGHUE and T. R. HYLAN
Antidepressant use in clinical practice: efficacy v. effectiveness
The British Journal of Psychiatry,
September 1, 2001;
179
(42):
s9 - s17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abrams, P. M. Doraiswamy, A. C. Scates, and H. A. Sackeim
Relapse of Depression After Electroconvulsive Therapy
JAMA,
June 27, 2001;
285(24):
3087 - 3089.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. YOUNG
Recurrent unipolar depression requires prolonged treatment
The British Journal of Psychiatry,
April 1, 2001;
178(4):
294 - 295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E S Paykel
Continuation and maintenance therapy in depression
Br. Med. Bull.,
March 1, 2001;
57(1):
145 - 159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Whooley and G. E. Simon
Managing Depression in Medical Outpatients
N. Engl. J. Med.,
December 28, 2000;
343(26):
1942 - 1950.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Optimal Duration of Antidepressant Therapy
Journal Watch Psychiatry,
November 1, 1998;
1998(1101):
18 - 18.
[Full Text]
|
|
|
|
|
|
|
Optimal Duration of Antidepressant Therapy
Journal Watch (General),
September 29, 1998;
1998(929):
7 - 7.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
